Please provide your email address to receive an email when new articles are posted on . Patients with PBC and cirrhosis treated with seladelpar exhibited greater reductions in ALP, GGT and ALT at 12 ...
New study finds promising treatment for cognitive deficits associated with cholestatic liver disease
Philadelphia, December 6, 2022 – Patients with cholestatic liver disease such as primary biliary cholangitis (PBC) can experience significant impairment of bile flow and may develop neurological ...
Drug-induced liver injury (DILI) is a harmful reaction to medications, herbs, and dietary supplements that results in liver dysfunction. Based on the distinct clinical patterns of liver damage, DILI ...
With smart DMPK strategies, cross-domain collaboration, and strong CDMO support, companies are pushing past the challenges of ...
A global study reveals that cutting-edge cancer immunotherapies, while lifesaving, carry a hidden risk: they may trigger cholestasis, a serious liver condition where bile flow stalls. Analyzing 634 ...
Kayfanda® (odevixibat) approved as new treatment choice for cholestatic pruritus in children from six months with the rare liver condition, Alagille Syndrome E.U. marketing authorization for Kayfanda ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback